Search This Blog

Monday, August 5, 2019

Mirati Therapeutics reports Q2 results

Mirati Therapeutics (NASDAQ:MRTX): Q2 GAAP EPS of -$1.26.
Revenue of $0.58M
Cash, cash equivalents, and short-term investments of $485.5M
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)